Since both contain semaglutide, their side-effect profiles are similar — most commonly nausea, vomiting, and diarrhoea. Wegovy uses a...

On the NHS, costs are set through commercial arrangements and are not always public, while in private practice the listed prices for...

Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required. They work differently: Wegovy (a GLP-1 receptor agonist) reduces appetite, slows stomach emptying, and boosts insulin release, while metformin mainly reduces glucose production in the liver and improves insulin sensitivity. Why these medicines are combined Doctors frequently prescribe Wegovy (semaglutide) alongside metformin, particularly in

In a head-to-head trial published in The New England Journal of Medicine , people taking Wegovy lost on average about 15.8% of their body weight over 68 weeks compared with 6.4% for those on Saxenda (liraglutide). This makes Wegovy the more effective of the two for weight loss in most cases. Two GLP-1 medicines, one key difference Both Wegovy and Saxenda belong to the same class of medicines, known as GLP-1 receptor agonists. They work by mimicking a natural hormone that redu

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type 2 diabetes. Weight changes with dulaglutide are usually modest compared with the significant reductions seen in trials of semaglutide for obesity. Two GLP-1 medicines, two purposes Both Wegovy and Trulicity belong to the same broad group of medicines known as GLP-1 receptor agonists. They mimic a natural hormone in the body that helps reduce

They’re not the same product: both contain semaglutide, but Wegovy is the weight-management brand (higher dose) and Ozempic is the type-2-diabetes brand (lower dose ranges). Indications, dosing schedules, and pens differ, so switching should be guided by a prescriber. Same ingredient, different goals It’s true that both Wegovy and Ozempic are based on semaglutide, a GLP-1 receptor agonist that helps regulate appetite, digestion, and blood sugar. But they were developed for di

For weight management, Wegovy (semaglutide 2.4 mg weekly) is the licensed option and generally achieves greater weight loss than the...

Choosing between Wegovy and Mounjaro comes down to what you’re aiming for (weight, blood sugar, side-effect profile) and what’s available to you. Many people see strong results with both; tirzepatide can yield greater reductions for some, while semaglutide has a longer real-world track record. Why these two drugs stand out Wegovy and Mounjaro are often compared because they’re part of the same family of treatments known as incretin-based medicines. Both act on hormones that h

Wegovy contains semaglutide, a GLP-1 receptor agonist used at higher weekly doses for weight management. It helps reduce appetite and supports lower energy intake alongside everyday habits like balanced eating and movement. What semaglutide actually is Semaglutide is a medicine that mimics GLP-1 (glucagon-like peptide-1), a natural hormone in the body. GLP-1 plays a key role in appetite and metabolism: it slows the emptying of the stomach, enhances the release of insulin when

Wegovy and Ozempic share the same active ingredient (semaglutide), but they’re licensed for different uses and doses — Wegovy for weight...

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both effective; some studies show larger average weight loss with tirzepatide, but individual response, side-effects, access, and clinical goals matter. The “better” choice is the one that fits your health needs and tolerability after a clinician review. Two medicines, two mechanisms Wegovy and Mounjaro both belong to a family of medicines that mimic natural gut hormones involved in appetite and metabolism. Wegovy contains s

Many people report fewer intrusive food thoughts, less urgency around snacking, and improved control in situations that previously triggered overeating. That can ease emotional or stress-linked eating because the immediate pull of ultra-palatable foods is quieter. Wegovy isn’t a treatment for mental-health conditions, so ongoing support — sleep, stress tools, counselling if needed — remains important. If mood changes occur, tell your clinical team so they can review and suppo

Wegovy isn’t licensed in the UK to treat fatty liver or other conditions directly, but weight reduction can improve liver fat and broader...

Storage is straightforward: keep pens in the refrigerator in their original carton, and do not freeze. Protect from light and check the...

Wegovy acts directly on GLP-1 receptors; effects on ghrelin and leptin are indirect and vary between individuals. By strengthening...

Wegovy is a once-weekly subcutaneous injection given into the abdomen, thigh, or upper arm. Rotate sites each week and avoid areas that...

The duration is guided by your response, tolerability, and local commissioning policy. Services typically build in review points — for example, at six months and at later milestones — to check progress and decide on continuation. Some pathways set a maximum course length; others allow ongoing use if agreed benchmarks are met within specialist care. Your team will set expectations clearly at the start so you know how and when decisions will be made. Why duration is not the sam

There isn’t a one-off loading dose; instead there’s a gradual dose-escalation (titration) phase. You start low and step up in stages...

After stopping, many people regain some weight over time because appetite signals gradually return toward baseline. How much and how quickly varies, but the pattern is common across all weight-management approaches. Planning ahead helps: keep protein intake consistent, maintain activity that preserves strength, and agree a follow-up plan with your team (for example, a slower taper, maintenance strategies, or alternative support). If you stop because goals have been met, expec

Yes — both men and women can use Wegovy when they meet eligibility criteria. Because exposure in pregnancy isn’t recommended, women of child-bearing potential are advised to use effective contraception and to discuss stopping in advance if planning a pregnancy. If you become pregnant, contact your clinical team promptly to review treatment. Apart from pregnancy and breastfeeding considerations, the approach to dosing and monitoring is similar across genders. Equal access in e